78 citations,
April 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
44 citations,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
234 citations,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
1 citations,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
23 citations,
October 2015 in “Andrology” New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
16 citations,
June 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
67 citations,
February 2006 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
20 citations,
February 2017 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
9 citations,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
36 citations,
June 2017 in “Journal of Cutaneous Medicine and Surgery” The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.
24 citations,
July 2013 in “Oncologist” Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
40 citations,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
182 citations,
August 2018 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
24 citations,
June 2018 in “Expert Review of Pharmacoeconomics & Outcomes Research” Microneedle technology is beneficial for drug delivery and could make vaccinations cheaper and more accessible.
38 citations,
March 2017 in “Expert Opinion on Investigational Drugs” Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.
July 2003 in “Journal of Cutaneous Medicine and Surgery” The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.
131 citations,
October 2004 in “Clinical Cancer Research” Tempol is safe and may prevent hair loss from brain radiotherapy.
4 citations,
December 2021 in “Archivio italiano di urologia andrologia” Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
6 citations,
September 2019 in “Skin pharmacology and physiology” RCS-01 therapy is safe and may improve skin structure by affecting gene expression.
June 2024 in “Nature Cell and Science” The Scalp Coverage Scoring method reliably measures hair density from images.
1 citations,
February 2004 Skin diseases are common and can significantly affect people's lives; better outcome measures and ethical clinical trials are needed to improve dermatology care.
August 2022 in “medRxiv (Cold Spring Harbor Laboratory)” The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.
93 citations,
August 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
1461 citations,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
3 citations,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
September 2021 in “VNU Journal of Science: Medical and Pharmaceutical Sciences” Platelet-rich plasma, which has growth factors, is used in many medical fields and can promote tissue repair, stimulate hair growth, and increase hair density.
3 citations,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
251 citations,
October 2014 in “The Journal of Clinical Endocrinology & Metabolism” The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.
306 citations,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.